MoneyWorks4Me

Molbio Diagnostics lists with 21% premium on the BSE

17 Aug 2026 Evaluate

Molbio Diagnostics has debuted at Rs 980.00 on the BSE, up by 173.00 points or 21.44% from its issue price of Rs 807.

The scrip is currently trading at Rs. 1018.00, up by 211.00 points or 26.15% from its issue price.

It has touched a high and low of Rs. 1,044.75 and Rs. 925.80 respectively. So far 11.54 lakh shares were traded on the counter.

The offering, which was open for subscription August 10, 2026 and August 12, 2026 was subscribed 70.27 times. The issue price was fixed at Rs 807 per share i.e. at upper end of price band of Rs 768 - 807 apiece.

Molbio Diagnostics is an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.

Molbio Diagnostics Share Price

1067.25 26.90 (2.59%)
20-Aug-2026 10:09 View Price Chart
Peers
Company Name CMP
Lenskart Solutions 643.25
Poly Medicure 1776.95
Molbio Diagnostics 1067.25
Laxmi Dental 202.30
Nureca 313.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: